A Phase 2 interventional study of elamipretide (MTP-131) 1% topical ophthalmic solution and Vehicle topical ophthalmic solution in Leber's Hereditary Optic Neuropathy, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-11-30.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Optic Atrophy, Hereditary, Leber · United States.
Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2016, is one of 3 in phase 2, and was the 10th registered.
44 studies on the registry are indexed under Optic Atrophy, Hereditary, Leber; 9 are open to participants now.
Browse Optic Atrophy, Hereditary, Leber studies →4 of the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in United States, Australia, Belgium and 7 more countries
Ages 6+
Randy Kardon · Sites in United States
Ages 18–99 · Healthy volunteers
MD Stem Cells · Sites in United States, Austria, United Arab Emirates
Ages 18+
Columbia University · Sites in United States, Canada
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Optic Atrophy, Hereditary, Leber studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 6 · Phase 4 1
First in 2010; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 36 across 31 interventional studies indexed under Optic Atrophy, Hereditary, Leber.
Median enrollment 36 across the 19 interventional studies, 44 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 1 study filed under Optic Atrophy, Hereditary, Leber — fewer than ten, so there is no comparison to draw.
3 of the studies in Optic Atrophy, Hereditary, Leber with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, prospective, randomized, double-masked, vehicle controlled, single-center study in approximately 12 subjects with LHON to evaluate safety, tolerability and efficacy of elamipretide (MTP-131) topical ophthalmic solution in this patient population. At the conclusion of 52 weeks of treatment, subjects will be offered the opportunity to enter an Open Label Extension for up to 48 additional weeks of treatment.
This was a prospective, randomized, double-masked (DM), vehicle-controlled, single-center study plus open label extension period (OLE) in which approximately 12 subjects with LHON having the genetic mtDNA mutation m.11778G>A were randomized in a masked manner into 1 of 3 groups in a 1:1:1 ratio: one drop of elamipretide 1.0% topical ophthalmic solution twice daily (BID) in the: left eye, right eye, or both eyes.
After completion of the 52-week treatment period or the Week 56 follow-up period, subjects were invited to participate in the OLE period for up to 108 weeks. During the OLE participants received 1% topical opthalmic elamipretide in both eyes (OU) daily. If a subject did not consent to the OLE, he/she completed the study at the Week 56 (±7 days) visit. There were 4 periods in this study: (1) screening period (up to 6 weeks); (2) double-masked treatment period (52 weeks); (3) OLE period (up to 108 weeks), and (4) follow-up period (4 weeks) after completion of End-of-Treatment (EOT) visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
Drug: elamipretide (MTP-131) 1% topical ophthalmic solution · Drug: Vehicle topical ophthalmic solution
One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
Drug: elamipretide (MTP-131) 1% topical ophthalmic solution · Drug: Vehicle topical ophthalmic solution
One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
Drug: elamipretide (MTP-131) 1% topical ophthalmic solution
One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
Drug: elamipretide (MTP-131) 1% topical ophthalmic solution
Also known as: MTP-131, Bendavia
Double Masked Period: Incidence of Ocular TEAEs
The incidence of ocular treatment emergent adverse events (TEAEs).
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Open Label Extension: Incidence of Ocular TEAEs
Open Label Extension: The incidence of ocular treatment emergent adverse events (TEAEs).
Time frame: Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Double Masked Period: Severity of Ocular TEAEs
The severity of ocular treatment emergent adverse events (TEAEs).
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
OLE: Severity of Ocular TEAEs
The severity of ocular treatment emergent adverse events (TEAEs).
Time frame: Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Double Masked Period: Best Corrected Visual Acuity (BCVA)
Double Masked Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Open Label Extension Period: Best Corrected Visual Acuity (BCVA) Using the Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale
Open Label Extension Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160 (follow-up visit).
Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude
Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude
Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) B-wave Amplitude
Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave amplitude by visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number mean a better outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: PhNR-ERG B-wave Amplitude
Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number means a better outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: PhNR Amplitude
Double Masked Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: PhNR Amplitude
Open Label Extension Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: PhNR/B-wave Amplitude Ratio
Double Masked Period: Change from baseline in PhNR/b-wave amplitude ratio by Visit. Photopic negative response electroretinography (PhNR assesses retinal cell function. A decrease in PhNR amplitude means worse outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: Change From Baseline by Visit PhNR/b Wave Amplitude Ratio
Open Label Extension Period: Change from baseline by visit PhNR/b Wave Amplitude Ratio by visit. A reduced amplitude ratio equals worse outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude
Double Masked Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. Calculated as (b-wave amplitude - PhNR amplitude)/a-wave amplitude. A reduced amplitude ratio equals worse outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude
Open Label Extension Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. \[Calculated by b-wave amplitude - PhNR amplitude)/a-wave amplitude.\] Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. A reduced amplitude ratio equals worse outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: PhNR Peak to Trough Amplitude (Unadjusted) From Baseline
Double Masked Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. Calculated as b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in amplitude is associated with worse outcomes.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: PhNR Peak to Trough Amplitude (Unadjusted)
Open Label Extension Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked: VFQ-39 Composite
Double Masked: Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Composite Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score.National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Open Label Extension Period: VFQ-39 General Health Score
Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 General Vision Score
Change from baseline in VFQ-39 General Vision Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 General Vision Score
Change from baseline in VFQ-39 General Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Ocular Pain Score
Change from baseline in VFQ-39 Ocular Pain score. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Ocular Pain Score
Change from baseline in VFQ-39 Ocular Pain score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Near Activities Score
Change from Baseline in VFQ-39 Near Activities Score from Baseline. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Near Activities
Change from Baseline in Visual Function Questionnaire (VFQ-39) Near Activities score.. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; score ranges from 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness
Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.
Time frame: Assessed at Baseline and Week 52 (end-of-treatment visit)
Open Label Extension Period: Retinal Nerve Fiber Layer Thickness
Open Label Extension Period: Change from baseline in Retinal Nerve Fiber Layer Thickness by SD-OCT by visit. Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.
Time frame: Assessed at Baseline, Week 148
Double Masked Period: Visual Field Mean Deviation as Measured by Humphrey Automated Visual Field Testing Stimulus III
Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Open Label Extension Period: Visual Field Mean Deviation (dB) Measured by Humphrey From Baseline
Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: Color Discrimination - Number of Plates
Double Masked Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit)
Open Label Extension Period: Change From Baseline in Color Discrimination - Number of Plates by Visit
Open Label Extension Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Period: Change From Baseline in Contrast Sensitivity by Pelli-Robson Contrast Sensitivity Chart by Visit
Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly.The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.
Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit)
Open Label Extension Period: Change From Baseline in Contrast Sensitivity by Visit
Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly. The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.
Time frame: Assessed at each visit from Baseline from Week 68 to Week 160
Double Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness
Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT From Baseline by Visit
Time frame: Assessed at Baseline and Week 52 (end-of-treatment visit)
Open Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness
Open Label Extension Period: Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT by SD-OCT by visit
Time frame: Assessed at Baseline, Week 148,
Double Masked: VFQ-39 Distance Activities Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Distance Activities score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Distance Activities Score
Change in Visual Function Questionnaire (VFQ-39) Distance Activities Score.National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Open Label Extension Period: VFQ-39 Social Functioning Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Social Functioning Score.
Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Double Masked: VFQ-39 Mental Health Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Mental Health Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Role Difficulties Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties score National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Role Difficulties Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Open Label Extension Period:VFQ-39 Dependency Score
Change from baseline in Visual Function Questionnaire (VFQ-39 ) Dependency Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Dependency Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Dependency score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Double Masked: VFQ-39 Color Vision Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: VFQ-39 Color Vision Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked: VFQ-39 Peripheral Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Open Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score
Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 160 (End of OLE Period)
Double Masked Period: Change in Intraocular Pressure (IOP)
Double Masked Period: Change in intraocular Pressure (IOP) in mmHg from Baseline by Visit
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Open Label Extension Period: Intraocular Pressure (IOP)
Change from baseline in Intraocular Pressure (IOP) in mmHg by Visit.
Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
OLE: Slit Lamp Examination (SLE)-Vehicle Eye
Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Vehicle Eyes
Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
OLE: Slit Lamp Examination (SLE)-Elamipretide Eye
Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Elamipretide Eyes
Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Double Masked: Slit Lamp Changes From Baseline: Vehicle Eye and Elamipretide Eye
Incidence of Change from normal or Abnormal, clinically insignificant to normal clinically significant
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Double Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes
Double Masked: Dilated Fundus Changes from Baseline: Vehicle Eye and Elamipretide Eyes Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant
Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Open Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes
Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant
Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Double Masked: VFQ-39 General Health Score
Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
| Milestone | Group 2 | Group 3 |
|---|---|---|
| Started | 8 | 4 |
| Completed | 8 | 4 |
| Not completed | 0 | 0 |
| Milestone | Group 2 | Group 3 |
|---|---|---|
| Started | 8 | 4 |
| Completed | 8 | 3 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The incidence of ocular treatment emergent adverse events (TEAEs).
| eyes | Double Masked Group Vehicle Eyes | Double Masked Group Elamipretide Eyes |
|---|---|---|
| Conjunctival hyperaemia | 3 | 8 |
| Punctate keratitis | 1 | 3 |
| Dry eye | 0 | 3 |
| Eye irritation | 1 | 2 |
| Eyelid irritation | 1 | 2 |
| Eyelid exfoliation | 1 | 1 |
| Lacrimation increased | 0 | 2 |
| Choroidal neovascularisation | 0 | 1 |
| Conjunctival oedema | 0 | 1 |
| Eyelid oedema | 0 | 1 |
| Noninfective conjunctivitis | 0 | 1 |
| Immune system disorders: Hypersensitivity | 1 | 1 |
| Infections and infestations Conjunctivitis | 1 | 1 |
| Injury, poisoning and procedural complications: Foreign body in eye | 0 | 1 |
| Injury, poisoning and procedural complications: Skin abrasion | 0 | 1 |
| Investigations: Intraocular pressure increased | 1 | 1 |
| Nervous system disorders: Parosmia | 0 | 2 |
Open Label Extension: The incidence of ocular treatment emergent adverse events (TEAEs).
| eyes | Double Masked Group Vehicle Eyes | Double Masked Group Elamipretide Eyes |
|---|---|---|
| Eye disorders Cataract nuclear | 1 | 1 |
| Eye disorders Ocular hyperaemia | 1 | 1 |
| Eye disorders Dry eye | 1 | 1 |
| Eye disorders Eye irritation | 2 | 1 |
| Eye disorders Eyelid irritation | 1 | 1 |
| Eye disorders Visual acuity reduced | 1 | 1 |
| Eye disorders Visual impairment | 0 | 2 |
| Eye disorders Punctate keratitis | 1 | 0 |
| General disorders and administration site conditions Application site pain (eyes burn, vision worse) | 3 | 5 |
| Immune system disorders Seasonal allergy (worsening vision in eyes) | 1 | 1 |
| Injury, poisoning and procedural complications: Corneal abrasian | 1 | 0 |
| Injury, poisoning and procedural complications: Eye contusion | 0 | 1 |
| Injury, poisoning and procedural complications: Fall (resulting in black eye) | 0 | 1 |
The severity of ocular treatment emergent adverse events (TEAEs).
| eyes | Vehicle Eyes: Mild | Vehicle Eyes: Moderate | Vehicle Eyes: Severe | Elamipretide Eyes: Mild | Elamipretide Eyes: Moderate | Elamipretide Eyes: Severe |
|---|---|---|---|---|---|---|
| Conjunctival hyperaemia | 2 | 0 | 0 | 1 | 1 | 0 |
| Punctate keratitis | 1 | 0 | 0 | 3 | 0 | 0 |
| Dry eye | 0 | 0 | 0 | 3 | 0 | 0 |
| Eye irritation | 1 | 0 | 0 | 2 | 0 | 0 |
| Eyelid irritation | 1 | 0 | 0 | 2 | 0 | 0 |
| Eyelid exfoliation | 1 | 0 | 0 | 1 | 0 | 0 |
| Lacrimation increased | 0 | 0 | 0 | 2 | 0 | 0 |
| Choroidal neovascularisation | 2 | 0 | 0 | 0 | 0 | 1 |
| Conjunctival oedema | 0 | 0 | 0 | 1 | 0 | 0 |
| Eyelid oedema | 0 | 0 | 0 | 1 | 0 | 0 |
| Noninfective conjunctivitis | 0 | 0 | 0 | 0 | 1 | 0 |
| Immune system disorders: Hypersensitivity | 1 | 0 | 0 | 1 | 0 | 0 |
| Infections and infestations Conjunctivitis | 0 | 1 | 0 | 0 | 1 | 0 |
| Injury, poisoning and procedural complications: Foreign body in eye | 0 | 0 | 0 | 1 | 0 | 0 |
| Injury, poisoning and procedural complications: Skin abrasion | 0 | 0 | 0 | 1 | 0 | 0 |
| Investigations: Intraocular pressure increased | 0 | 1 | 0 | 0 | 1 | 0 |
| Nervous system disorders: Parosmia | 0 | 0 | 0 | 2 | 0 | 0 |
The severity of ocular treatment emergent adverse events (TEAEs).
| eyes | Vehicle to Elamipretide Eyes: Mild | Vehicle to Elamipretide Eyes: Moderate | Vehicle to Elamipretide Eyes: Severe | Elamipretide to Elamipretide Eyes: Mild | Elamipretide to Elamipretide Eyes: Moderate | Elamipretide to Elamipretide Eyes: Severe |
|---|---|---|---|---|---|---|
| Eye disorders Cataract nuclear | 5 | 0 | 0 | 6 | 0 | 0 |
| Punctate keratitis | 1 | 0 | 0 | 0 | 0 | 0 |
| Dry eye | 1 | 0 | 0 | 1 | 0 | 0 |
| Eye irritation | 2 | 0 | 0 | 1 | 0 | 0 |
| Eyelid irritation | 1 | 0 | 0 | 1 | 0 | 0 |
| Ocular hyperaemia | 1 | 0 | 0 | 1 | 0 | 0 |
| Visual acuity reduced | 1 | 0 | 0 | 1 | 0 | 0 |
| Visual impairment | 0 | 0 | 0 | 2 | 0 | 0 |
| General disorders and administration site conditions Application site pain | 3 | 0 | 0 | 5 | 0 | 0 |
| Immune system disorders Seasonal allergy | 1 | 0 | 0 | 1 | 0 | 0 |
| Injury, poisoning and procedural complications Corneal abrasian | 1 | 0 | 0 | 0 | 0 | 0 |
| Injury, poisoning and procedural complications Eye contusion | 0 | 0 | 0 | 1 | 0 | 0 |
| Injury, poisoning and procedural complications: Fall | 0 | 0 | 0 | 1 | 0 | 0 |
Double Masked Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
| letters | Double Masked Group Vehicle Eyes | Double Masked Group Elamipretide Eyes |
|---|---|---|
| Day 5 | -3.1 ± 9.34 | -0.5 ± 4.50 |
| Week 4 | 0.3 ± 3.33 | 1.0 ± 3.54 |
| Week 8 | 2.0 ± 3.02 | 0.5 ± 5.29 |
| Week 12 | 2.8 ± 5.15 | 0.4 ± 6.47 |
| Week 16 | 3.0 ± 3.38 | 0.6 ± 4.06 |
| Week 20 | 4.0 ± 10.42 | 1.7 ± 4.63 |
| Week 24 | 4.1 ± 9.98 | 2.1 ± 3.79 |
| Week 28 | 5.5 ± 11.99 | 1.4 ± 4.99 |
| Week 32 | 4.8 ± 15.54 | 2.7 ± 7.67 |
| Week 36 | 6.6 ± 11.73 | 1.9 ± 4.53 |
| Week 40 | 2.6 ± 11.56 | 3.2 ± 4.40 |
| Week 44 | 6.1 ± 11.85 | 3.5 ± 5.97 |
| Week 48 | 5.1 ± 16.58 | 4.8 ± 4.89 |
| Week 52 | 4.6 ± 16.27 | 2.9 ± 5.45 |
| Week 56 (follow up Visit) | 1.7 ± 2.89 | 5.3 ± 4.16 |
Open Label Extension Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
| letters | Vehicle to Elamipretide | Elamipretide to Elamipretide |
|---|---|---|
| Week 68 | 8.5 ± 14.16 | 6.00 ± 7.18 |
| Week 84 | 10.6 ± 18.66 | 5.4 ± 7.70 |
| Week 100 | 6.1 ± 13.86 | 6.1 ± 6.12 |
| Week 104 | -3.5 ± 6.36 | 2.5 ± 0.71 |
| Week 116 | 11.3 ± 14.00 | 5.9 ± 6.71 |
| Week 132 | 11.6 ± 17.04 | 4.3 ± 8.36 |
| Week 148 | 2.8 ± 2.50 | 2.9 ± 4.05 |
| Week 160 | 1.7 ± 2.08 | 7.7 ± 4.16 |
Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.
| µV | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | 0.0 ± 6.61 | 1.3 ± 6.81 |
| Week 8 | -0.2 ± 6.92 | 0.5 ± 7.50 |
| Week 12 | -3.5 ± 11.09 | -3.2 ± 10.18 |
| Week 16 | 1.1 ± 6.71 | 0.7 ± 6.30 |
| Week 20 | 1.5 ± 4.64 | 1.1 ± 4.71 |
| Week 24 | 2.0 ± 6.18 | 2.0 ± 6.56 |
| Week 28 | 0.4 ± 5.11 | 2.5 ± 5.80 |
| Week 32 | 2.0 ± 8.18 | 0.3 ± 5.64 |
| Week 36 | -2.5 ± 11.62 | 0.2 ± 7.00 |
| Week 40 | 2.2 ± 10.07 | 1.5 ± 6.28 |
| Week 44 | 1.0 ± 11.05 | 3.2 ± 6.55 |
| Week 48 | 3.4 ± 8.31 | 2.9 ± 6.19 |
| Week 52 | 2.3 ± 5.58 | 2.0 ± 5.16 |
| Week 56 (Follow up Visit) | 7.0 ± 2.93 | 5.1 ± 8.71 |
Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.
| µV | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | 3.2 ± 9.24 | 4.0 ± 6.00 |
| Week 84 | -7.1 ± 19.27 | 1.8 ± 6.81 |
| Week 100 | 8.0 ± 5.69 | 4.9 ± 4.41 |
| Week 104 | 5.3 ± 3.27 | 3.0 ± 1.71 |
| Week 116 | -2.7 ± 9.39 | 0.3 ± 5.93 |
| Week 132 | 5.7 ± 7.07 | 1.4 ± 3.99 |
| Week 148 | 5.4 ± 8.92 | 1.5 ± 3.84 |
| Week 160 | 2.9 ± 2.82 | 2.82 ± 7.60 |
Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave amplitude by visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number mean a better outcome.
| µV | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | -9.1 ± 14.36 | -4.5 ± 31.48 |
| Week 8 | -4.6 ± 21.82 | -3.4 ± 22.33 |
| Week 12 | 3.5 ± 17.85 | 14.6 ± 27.23 |
| Week 16 | -2.8 ± 28.02 | -2.6 ± 19.83 |
| Week 20 | -2.2 ± 22.48 | -6.4 ± 29.35 |
| Week 24 | -8.9 ± 20.58 | -1.0 ± 28.06 |
| Week 28 | -0.7 ± 19.04 | -11.6 ± 17.75 |
| Week 32 | -5.6 ± 13.57 | 1.8 ± 24.58 |
| Week 36 | 2.4 ± 29.87 | 2.2 ± 22.06 |
| Week 40 | -0.1 ± 23.58 | -8.1 ± 23.17 |
| Week 44 | 1.9 ± 21.35 | -5.0 ± 21.01 |
| Week 48 | -6.9 ± 24.08 | -10.5 ± 23.80 |
| Week 52 | -1.3 ± 13.97 | -5.4 ± 18.99 |
| Week 56 (Follow up) | -18.4 ± 28.05 | -17.5 ± 49.57 |
Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number means a better outcome.
| µV | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -15.4 ± 25.98 | -7.4 ± 17.10 |
| Week 84 | -6.0 ± 23.97 | -13.1 ± 20.97 |
| Week 100 | -28.7 ± 23.23 | -19.9 ± 18.04 |
| Week 104 | -17.7 ± 5.23 | -14.2 ± 4.62 |
| Week 116 | 17.1 ± 44.40 | 4.9 ± 18.79 |
| Week 132 | -17.1 ± 17.08 | -1.3 ± 18.81 |
| Week 148 | -13.1 ± 30.88 | -7.3 ± 18.84 |
| Week 160 | -17.8 ± 14.15 | -38.1 ± 25.20 |
Double Masked Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.
| µV | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | -6.4 ± 22.27 | 0.3 ± 22.05 |
| Week 8 | -4.6 ± 26.80 | -3.3 ± 27.28 |
| Week 12 | -11.6 ± 26.59 | -0.7 ± 14.90 |
| Week 16 | -4.5 ± 10.26 | -3.1 ± 17.35 |
| Week 20 | 0.5 ± 20.65 | -3.1 ± 19.58 |
| Week 24 | -4.3 ± 21.51 | -0.5 ± 16.15 |
| Week 28 | -7.1 ± 26.32 | -1.5 ± 13.92 |
| Week 32 | -4.1 ± 25.11 | -3.1 ± 13.61 |
| Week 36 | -8.5 ± 24.94 | -3.4 ± 10.17 |
| Week 40 | -2.3 ± 23.16 | -4.4 ± 10.92 |
| Week 44 | -9.8 ± 29.75 | -1.5 ± 11.91 |
| Week 48 | -2.8 ± 22.76 | -3.7 ± 13.14 |
| Week 52 | -4.0 ± 25.41 | -3.3 ± 11.73 |
| Week 56 (Follow up) | -1.6 ± 16.71 | -5.7 ± 6.45 |
Open Label Extension Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.
| µV | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -7.1 ± 22.91 | 0.5 ± 16.60 |
| Week 84 | -2.5 ± 25.45 | -2.2 ± 11.96 |
| Week 100 | 3.3 ± 16.25 | 1.8 ± 6.50 |
| Week 104 | 3.3 ± 1.03 | -1.2 ± 6.72 |
| Week 116 | -5.1 ± 20.89 | 0.4 ± 9.00 |
| Week 132 | -3.6 ± 20.98 | 0.5 ± 10.75 |
| Week 148 | -4.1 ± 8.75 | -1.4 ± 4.23 |
| Week 160 | -9.9 ± 4.31 | -10.0 ± 11.64 |
Double Masked Period: Change from baseline in PhNR/b-wave amplitude ratio by Visit. Photopic negative response electroretinography (PhNR assesses retinal cell function. A decrease in PhNR amplitude means worse outcome.
| ratio | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | -0.102 ± 0.2225 | -0.033 ± 0.2793 |
| Week 8 | -0.036 ± 0.3101 | -0.033 ± 0.3385 |
| Week 12 | -0.113 ± 0.2415 | 0.019 ± 0.1721 |
| Week 16 | -0.059 ± 0.1179 | -0.070 ± 0.2285 |
| Week 20 | -0.018 ± 0.2005 | -0.066 ± 0.2365 |
| Week 24 | -0.052 ± 0.2080 | 0.014 ± 0.2131 |
| Week 28 | -0.044 ± 0.2281 | -0.024 ± 0.1634 |
| Week 32 | -0.033 ± 0.2414 | -0.031 ± 0.1513 |
| Week 36 | -0.104 ± 0.2479 | -0.013 ± 0.1795 |
| Week 40 | -0.007 ± 0.2190 | -0.046 ± 0.1202 |
| Week 44 | -0.138 ± 0.3194 | 0.013 ± 0.2206 |
| Week 48 | -0.020 ± 0.2366 | -0.059 ± 0.1533 |
| Week 52 | -0.044 ± 0.2428 | -0.029 ± 0.1299 |
| Week 56 (Follow up) | 0.009 ± 0.2670 | -0.063 ± 0.1149 |
Open Label Extension Period: Change from baseline by visit PhNR/b Wave Amplitude Ratio by visit. A reduced amplitude ratio equals worse outcome.
| Ratio | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -0.097 ± 0.2453 | -0.002 ± 0.1722 |
| Week 84 | -0.021 ± 0.2678 | -0.041 ± 0.1207 |
| Week 100 | 0.012 ± 0.1523 | -0.003 ± 0.0796 |
| Week 104 | 0.019 ± 0.0066 | -0.048 ± 0.0667 |
| Week 116 | -0.034 ± 0.2112 | 0.000 ± 0.0971 |
| Week 132 | -0.055 ± 0.1957 | 0.032 ± 0.2010 |
| Week 148 | -0.035 ± 0.0717 | -0.046 ± 0.0982 |
| Week 160 | -0.155 ± 0.1075 | -0.212 ± 0.2211 |
Double Masked Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. Calculated as (b-wave amplitude - PhNR amplitude)/a-wave amplitude. A reduced amplitude ratio equals worse outcome.
| Ratio | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | 0.18 ± 0.392 | -0.21 ± 1.100 |
| Week 8 | -0.03 ± 0.655 | 1.08 ± 4.628 |
| Week 12 | 0.08 ± 0.827 | 0.00 ± 0.962 |
| Week 16 | -0.53 ± 1.260 | -0.01 ± 0.862 |
| Week 20 | -0.32 ± 0.992 | 0.10 ± 1.022 |
| Week 24 | -0.35 ± 0.856 | -0.29 ± 0.746 |
| Week 28 | -0.35 ± 0.819 | -0.21 ± 1.358 |
| Week 32 | -0.24 ± 0.820 | -0.15 ± 0.606 |
| Week 36 | -0.05 ± 0.687 | -0.70 ± 1.162 |
| Week 40 | 0.63 ± 0.546 | 0.02 ± 1.123 |
| Week 44 | -0.68 ± 0.438 | -0.66 ± 1.016 |
| Week 48 | -0.61 ± 0.811 | -0.31 ± 0.769 |
| Week 52 | -0.61 ± 0.291 | -0.37 ± 0.403 |
| Week 56 (Follow up) | -1.22 ± 0.114 | -0.87 ± 0.274 |
Open Label Extension Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. \[Calculated by b-wave amplitude - PhNR amplitude)/a-wave amplitude.\] Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. A reduced amplitude ratio equals worse outcome.
| Ratio | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -0.31 ± 1.006 | -0.70 ± 0.859 |
| Week 84 | 0.25 ± 1.700 | -0.09 ± 1.050 |
| Week 100 | -0.30 ± 0.591 | -0.13 ± 0.407 |
| Week 104 | -0.10 ± 0.454 | -0.09 ± 0.103 |
| Week 116 | -0.64 ± 1.189 | -0.46 ± 0.673 |
| Week 132 | -0.77 ± 0.831 | -0.38 ± 0.329 |
| Week 148 | -0.91 ± 0.609 | -0.16 ± 0.437 |
| Week 160 | -0.46 ± 0.457 | -0.92 ± 1.027 |
Double Masked Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. Calculated as b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in amplitude is associated with worse outcomes.
| µV | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | -2.72 ± 24.750 | -4.80 ± 31.025 |
| Week 8 | 0.08 ± 18.496 | -0.08 ± 31.421 |
| Week 12 | 15.16 ± 38.016 | 15.38 ± 33.898 |
| Week 16 | 1.70 ± 32.016 | 0.52 ± 25.629 |
| Week 20 | -2.62 ± 20.398 | -3.29 ± 21.498 |
| Week 24 | -4.57 ± 25.171 | -0.54 ± 30.470 |
| Week 28 | 6.38 ± 26.095 | -10.18 ± 19.504 |
| Week 32 | -1.42 ± 28.294 | 4.86 ± 26.750 |
| Week 36 | 10.94 ± 48.051 | 5.57 ± 26.427 |
| Week 40 | 2.22 ± 43.149 | -3.74 ± 27.206 |
| Week 44 | 11.74 ± 46.933 | -3.46 ± 26.042 |
| Week 48 | -4.12 ± 34.581 | -6.86 ± 28.849 |
| Week 52 | 2.73 ± 19.124 | -2.15 ± 22.109 |
| Week 56 (Follow up) | -16.78 ± 19.472 | -11.80 ± 49.865 |
Open Label Extension Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes.
| µV | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -8.36 ± 36.178 | -7.92 ± 21.402 |
| Week 84 | -3.50 ± 13.206 | -10.90 ± 22.928 |
| Week 100 | -32.02 ± 23.994 | -21.64 ± 21.432 |
| Week 104 | -21.01 ± 4.193 | -13.01 ± 11.340 |
| Week 116 | 22.26 ± 42.352 | 4.52 ± 22.231 |
| Week 132 | -13.56 ± 27.012 | -1.85 ± 15.341 |
| Week 148 | -8.99 ± 35.662 | -5.84 ± 19.242 |
| Week 160 | -7.87 ± 11.415 | -28.17 ± 31.249 |
Double Masked: Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 6.1 ± 5.63 | 5.7 ± 8.07 |
| Week 56 (Follow-up Visit) | 7.8 ± 7.02 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score.National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Composite Score | 5.6 ± 11.30 | 13.9 ± 8.66 |
Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 General Health Score | -6.8 ± 10.58 | 6.7 ± 11.55 |
Change from baseline in VFQ-39 General Vision Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 8.1 ± 8.84 | 1.3 ± 11.09 |
| Week 56 (Follow-up Visit) | 3.3 ± 7.64 | — |
Change from baseline in VFQ-39 General Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 General Vision Score | 9.3 ± 13.36 | 6.7 ± 11.55 |
Change from baseline in VFQ-39 Ocular Pain score. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 1.6 ± 12.39 | 3.1 ± 6.25 |
| Week 56 (Follow-up Visit) | 12.5 ± 12.50 | — |
Change from baseline in VFQ-39 Ocular Pain score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Ocular Pain Score | -16.1 ± 20.04 | -4.2 ± 7.22 |
Change from Baseline in VFQ-39 Near Activities Score from Baseline. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 3.6 ± 7.53 | 9.2 ± 9.41 |
| Week 56 (Follow-up Visit) | 11.1 ± 9.62 | — |
Change from Baseline in Visual Function Questionnaire (VFQ-39) Near Activities score.. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; score ranges from 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Near Activities | 8.5 ± 11.03 | 16.7 ± 16.67 |
Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.
| µm | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Double Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness | -3.8 ± 7.52 | -2.6 ± 4.76 |
Open Label Extension Period: Change from baseline in Retinal Nerve Fiber Layer Thickness by SD-OCT by visit. Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.
| µm | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Open Label Extension Period: Retinal Nerve Fiber Layer Thickness | -1.0 | 1.4 ± 2.70 |
Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.
| dB | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Week 4 | 1.1 ± 3.62 | 2.1 ± 3.94 |
| Week 8 | 0.5 ± 3.88 | 1.6 ± 3.82 |
| Week 12 | 0.4 ± 3.85 | 0.9 ± 3.42 |
| Week 16 | 0.3 ± 1.87 | 1.9 ± 2.62 |
| Week 20 | -0.4 ± 5.31 | 2.1 ± 4.23 |
| Week 24 | 2.0 ± 3.33 | 1.1 ± 2.74 |
| Week 28 | 1.7 ± 4.40 | 1.3 ± 4.86 |
| Week 32 | 2.9 ± 4.27 | 1.4 ± 4.38 |
| Week 36 | 2.6 ± 4.75 | 2.2 ± 3.55 |
| Week 40 | 2.8 ± 5.98 | 2.2 ± 3.55 |
| Week 44 | 1.8 ± 6.03 | 2.8 ± 5.10 |
| Week 48 | 1.5 ± 3.66 | 1.4 ± 3.92 |
| Week 52 | 0.9 ± 4.18 | 2.2 ± 3.30 |
| Week 56 (Follow up) | 3.7 ± 5.67 | 1.6 ± 3.53 |
Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.
| dB | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | 3.3 ± 5.59 | 4.0 ± 6.66 |
| Week 84 | 5.1 ± 6.66 | 4.4 ± 6.53 |
| Week 100 | 3.1 ± 6.85 | 5.5 ± 8.04 |
| Week 104 | 0.9 ± 0.97 | 2.9 ± 0.99 |
| Week 116 | 4.4 ± 5.48 | 4.7 ± 6.21 |
| Week 132 | 4.7 ± 8.43 | 4.0 ± 6.62 |
| Week 148 | 5.5 ± 8.16 | 5.6 ± 9.51 |
| Week 160 | 6.3 ± 13.67 | 11.5 ± 16.98 |
Double Masked Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.
| Plates | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Day 5 | 0.0 ± 0.00 | 0.1 ± 0.57 |
| Week 4 | 0.0 ± 0.00 | 0.1 ± 0.50 |
| Week 8 | 0.1 ± 0.35 | 0.3 ± 0.58 |
| Week 12 | 0.3 ± 0.71 | 0.2 ± 0.75 |
| Week 16 | 0.0 ± 0.00 | 0.4 ± 0.89 |
| Week 20 | 0.5 ± 0.93 | 0.3 ± 0.60 |
| Week 24 | 0.3 ± 0.71 | 0.5 ± 0.97 |
| Week 28 | 0.9 ± 1.36 | 0.8 ± 1.39 |
| Week 32 | 0.8 ± 1.16 | 0.7 ± 1.30 |
| Week 36 | 0.8 ± 1.16 | 0.8 ± 1.05 |
| Week 40 | 0.5 ± 0.76 | 0.6 ± 0.81 |
| Week 44 | 1.0 ± 1.07 | 0.9 ± 1.31 |
| Week 48 | 1.3 ± 1.39 | 1.1 ± 1.34 |
| Week 52 | 1.6 ± 1.60 | 1.1 ± 1.09 |
| Week 56 (Follow up) | 1.7 ± 2.89 | 1.0 ± 1.00 |
Open Label Extension Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.
| plates | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | 1.3 ± 1.28 | 1.4 ± 1.36 |
| Week 84 | 1.9 ± 1.96 | 1.6 ± 1.75 |
| Week 100 | 2.8 ± 3.65 | 2.0 ± 2.54 |
| Week 104 | 0.0 ± 0.00 | 0.5 ± 0.71 |
| Week 116 | 2.4 ± 2.70 | 1.2 ± 1.92 |
| Week 132 | 2.0 ± 1.83 | 1.6 ± 1.33 |
| Week 148 | 1.0 ± 0.82 | 0.9 ± 0.35 |
| Week 160 | 2.0 ± 2.00 | 1.3 ± 1.53 |
Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly.The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.
| score on a scale | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Day 5 | 0.075 ± 0.0802 | -0.019 ± 0.1078 |
| Week 4 | 0.038 ± 0.0694 | -0.028 ± 0.1366 |
| Week 8 | 0.075 ± 0.1134 | 0.047 ± 0.1420 |
| Week 12 | 0.056 ± 0.1116 | 0.000 ± 0.1342 |
| Week 16 | 0.075 ± 0.1134 | -0.009 ± 0.1020 |
| Week 20 | 0.094 ± 0.1116 | -0.009 ± 0.1020 |
| Week 24 | 0.075 ± 0.1134 | 0.028 ± 0.1663 |
| Week 28 | 0.113 ± 0.1747 | -0.009 ± 0.1393 |
| Week 32 | 0.113 ± 0.1553 | 0.028 ± 0.1663 |
| Week 36 | 0.150 ± 0.1604 | 0.056 ± 0.1806 |
| Week 40 | 0.206 ± 0.1782 | 0.075 ± 0.1975 |
| Week 44 | 0.225 ± 0.2268 | 0.066 ± 0.2625 |
| Week 48 | 0.188 ± 0.2232 | 0.084 ± 0.1446 |
| Week 52 | 0.225 ± 0.2121 | 0.075 ± 0.2258 |
| Week 56 (Follow up) | 0.100 ± 0.0866 | 0.050 ± 0.0866 |
Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly. The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.
| score on a scale | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | 0.225 ± 0.2121 | 0.084 ± 0.1972 |
| Week 84 | 0.300 ± 0.1964 | 0.122 ± 0.1991 |
| Week 100 | 0.281 ± 0.2034 | 0.118 ± 0.2893 |
| Week 104 | 0.075 ± 0.1061 | 0.075 ± 0.1061 |
| Week 116 | 0.300 ± 0.3000 | 0.196 ± 0.2626 |
| Week 132 | 0.214 ± 0.1909 | 0.127 ± 0.2796 |
| Week 148 | 0.225 ± 0.2598 | 0.113 ± 0.1553 |
| Week 160 | 0.150 ± 0.2598 | 0.100 ± 0.0866 |
Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT From Baseline by Visit
| µm | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Double Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness | -1.5 ± 4.00 | -3.6 ± 13.49 |
Open Label Extension Period: Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT by SD-OCT by visit
| µm | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Open Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness | -1.0 | 3.4 ± 6.07 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Distance Activities score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 9.4 ± 12.94 | 0.0 ± 14.03 |
| Week 56 (Follow-up Visit) | 54.2 ± 14.43 | — |
Change in Visual Function Questionnaire (VFQ-39) Distance Activities Score.National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Distance Activities Score | 12.5 ± 20.56 | 13.9 ± 6.36 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Social Functioning Score | 8.3 ± 11.78 | 5.6 ± 17.35 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 6.3 ± 10.68 | 0.0 ± 19.25 |
| Week 56 (Follow-up Visit) | 16.7 ± 8.34 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 12.0 ± 9.16 | 19.7 ± 32.47 |
| Week 56 (Follow-up Visit) | 13.3 ± 25.17 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Mental Health Score | 16.4 ± 22.31 | 29.2 ± 29.83 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties score National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 4.7 ± 10.43 | 14.1 ± 9.38 |
| Week 56 (Follow-up Visit) | 10.4 ± 13.01 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Role Difficulties Score | 8.0 ± 12.87 | 37.5 ± 16.54 |
Change from baseline in Visual Function Questionnaire (VFQ-39 ) Dependency Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period:VFQ-39 Dependency Score | 16.1 ± 13.91 | 27.1 ± 3.61 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Dependency score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 9.4 ± 22.10 | -2.6 ± 24.85 |
| Week 56 (Follow-up Visit) | -8.3 ± 23.66 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 6.3 ± 17.68 | 6.3 ± 12.50 |
| Week 56 (Follow-up Visit) | 0.0 ± 25.00 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: VFQ-39 Color Vision Score | -7.1 ± 18.90 | 8.3 ± 14.43 |
Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | 0.0 ± 13.36 | 6.3 ± 12.50 |
| Week 56 (Follow-up Visit) | 66.7 ± 14.43 | — |
Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye in DM Period | Bilateral Eye in DM Period |
|---|---|---|
| Open Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score | 0.0 ± 32.27 | 0.0 ± 25.00 |
Double Masked Period: Change in intraocular Pressure (IOP) in mmHg from Baseline by Visit
| mmHg | Double Masked Group Vehicle Eyes | Double Masked Group Elamipretide Eyes |
|---|---|---|
| Day 5 | -0.3 ± 1.67 | -0.2 ± 1.87 |
| Week 4 | 0.0 ± 3.16 | -0.4 ± 2.16 |
| Week 8 | -0.4 ± 1.77 | -0.5 ± 1.83 |
| Week 12 | 0.5 ± 2.39 | -0.5 ± 2.53 |
| Week 16 | 0.4 ± 1.51 | 0.6 ± 3.14 |
| Week 20 | 0.4 ± 1.85 | -0.3 ± 1.66 |
| Week 24 | -0.1 ± 3.31 | -0.4 ± 2.99 |
| Week 28 | 0.3 ± 1.83 | 0.3 ± 1.88 |
| Week 32 | 0.0 ± 2.62 | -0.3 ± 1.92 |
| Week 36 | -1.1 ± 1.55 | -1.3 ± 1.96 |
| Week 40 | 0.3 ± 2.25 | -0.6 ± 1.75 |
| Week 44 | -0.4 ± 2.00 | -0.3 ± 1.85 |
| Week 48 | 0.5 ± 3.66 | 0.8 ± 2.79 |
| Week 52 | -1.0 ± 1.20 | -0.5 ± 2.66 |
| Week 56 (follow up Visit) | -1.0 ± 1.20 | -0.5 ± 2.66 |
Change from baseline in Intraocular Pressure (IOP) in mmHg by Visit.
| mmHg | Vehicle to Elamipretide Eyes | Elamipretide to Elamipretide Eyes |
|---|---|---|
| Week 68 | -0.4 ± 1.60 | 0.8 ± 2.49 |
| Week 84 | 1.4 ± 3.29 | 0.4 ± 2.37 |
| Week 100 | -0.9 ± 2.03 | -0.2 ± 2.22 |
| Week 104 | 1.5 ± 2.12 | -1.0 ± 1.41 |
| Week 116 | 0.1 ± 3.18 | -0.5 ± 2.63 |
| Week 132 | 0.1 ± 1.35 | 0.1 ± 1.80 |
| Week 148 | 1.3 ± 2.06 | -0.1 ± 2.36 |
| Week 160 | 0.7 ± 0.58 | -1.7 ± 1.53 |
Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Vehicle Eyes
| eyes | Normal to Abnormal CS | Shift From Abnormal NCS to Abnormal CS |
|---|---|---|
| Lids Eye Week 68 | 0 | 0 |
| Lids Week 84 | 0 | 0 |
| Lids Week 100 | 0 | 0 |
| Lids Week 104 | 0 | 0 |
| Lids Week 116 | 0 | 0 |
| Lids Week 132 | 0 | 0 |
| Lids Week 148 | 0 | 0 |
| Lids Week 160 | 0 | 0 |
| Conjunctiva 68 | 0 | 0 |
| Conjunctiva 84 | 0 | 0 |
| Conjunctiva 100 | 0 | 0 |
| Conjunctiva 104 | 0 | 0 |
| Conjunctiva 116 | 0 | 0 |
| Conjunctiva 132 | 0 | 0 |
| Conjunctiva 148 | 0 | 0 |
| Conjunctiva 160 | 0 | 0 |
| Cornea Week 68 | 0 | 0 |
| Cornea Week 84 | 1 | 0 |
| Cornea Week 100 | 1 | 0 |
| Cornea Week 104 | 0 | 0 |
| Cornea Week 116 | 0 | 0 |
| Cornea Week 132 | 0 | 0 |
| Cornea Week 148 | 0 | 0 |
| Cornea Week 160 | 0 | 0 |
| Anterior Chamber 68 | 0 | 0 |
| Anterior Chamber 84 | 0 | 0 |
| Anterior Chamber 100 | 0 | 0 |
| Anterior Chamber 104 | 0 | 0 |
| Anterior Chamber 116 | 0 | 0 |
| Anterior Chamber 132 | 0 | 0 |
| Anterior Chamber 148 | 0 | 0 |
| Anterior Chamber 160 | 0 | 0 |
| Iris Week 68 | 0 | 0 |
| Iris Week 84 | 0 | 0 |
| Iris Week 100 | 0 | 0 |
| Iris Week 104 | 0 | 0 |
| Iris Week 116 | 0 | 0 |
| Iris Week 132 | 0 | 0 |
| Iris Week 148 | 0 | 0 |
| Iris Week 160 | 0 | 0 |
| Lens Week 68 | 0 | 0 |
| Lens Week 84 | 0 | 0 |
| Lens Week 100 | 0 | 0 |
| Lens Week 104 | 0 | 0 |
| Lens Week 116 | 1 | 0 |
| Lens Week 132 | 0 | 0 |
| Lens Week 148 | 0 | 0 |
| Lens Week 160 | 0 | 0 |
| Vitreous Week 68 | 0 | 0 |
| Vitreous Week 84 | 0 | 0 |
| Vitreous Week 100 | 0 | 0 |
| Vitreous Week 104 | 0 | 0 |
| Vitreous Week 116 | 0 | 0 |
| Vitreous Week 132 | 0 | 0 |
| Vitreous Week 148 | 0 | 0 |
| Vitreous Week 160 | 0 | 0 |
| Retina Week 68 | 0 | 0 |
| Retina Week 84 | 0 | 0 |
| Retina Week 100 | 0 | 0 |
| Retina Week 104 | 0 | 0 |
| Retina Week 116 | 0 | 0 |
| Retina Week 132 | 0 | 0 |
| Retina Week 148 | 0 | 0 |
| Retina Week 160 | 0 | 0 |
| Optic nerve Week 68 | 0 | 0 |
| Optic nerve Week 84 | 0 | 0 |
| Optic nerve Week 100 | 0 | 0 |
| Optic nerve Week 104 | 0 | 0 |
| Optic nerve Week 116 | 0 | 0 |
| Optic nerve Week132 | 0 | 0 |
| Optic nerve Week 148 | 0 | 0 |
| Optic nerve Week 160 | 0 | 0 |
| Macula Week 68 | 0 | 0 |
| Macula Week 84 | 0 | 0 |
| Macula Week 100 | 0 | 0 |
| Macula Week 104 | 0 | 0 |
| Macula Week 116 | 0 | 0 |
| Macula Week 132 | 0 | 0 |
| Macula Week 148 | 0 | 0 |
| Macula Week 160 | 0 | 0 |
| Choroid Week 68 | 0 | 0 |
| Choroid Week 84 | 0 | 0 |
| Choroid Week 100 | 0 | 0 |
| Choroid Week 104 | 0 | 0 |
| Choroid Week 116 | 0 | 0 |
| Choroid Week 132 | 0 | 0 |
| Choroid Week 148 | 0 | 0 |
| Choroid Week 160 | 0 | 0 |
| Periphery Week 68 | 0 | 0 |
| Periphery Week 84 | 0 | 0 |
| Periphery Week 100 | 0 | 0 |
| Periphery Week 104 | 0 | 0 |
| Periphery Week 116 | 0 | 0 |
| Periphery Week 132 | 0 | 0 |
| Periphery Week 148 | 0 | 0 |
| Periphery 160 | 0 | 0 |
Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Elamipretide Eyes
| eyes | Normal to Abnormal CS | Shift From Abnormal NCS to Abnormal CS |
|---|---|---|
| Lids Eye Week 68 | 0 | 0 |
| Lids Week 84 | 0 | 0 |
| Lids Week 100 | 0 | 0 |
| Lids Week 104 | 0 | 0 |
| Lids Week 116 | 0 | 0 |
| Lids Week 132 | 0 | 0 |
| Lids Week 148 | 0 | 0 |
| Lids Week 160 | 0 | 0 |
| Conjunctiva 68 | 0 | 0 |
| Conjunctiva 84 | 0 | 0 |
| Conjunctiva 100 | 0 | 0 |
| Conjunctiva 104 | 0 | 0 |
| Conjunctiva 116 | 0 | 0 |
| Conjunctiva 132 | 0 | 0 |
| Conjunctiva 148 | 0 | 0 |
| Conjunctiva 160 | 0 | 0 |
| Cornea Week 68 | 0 | 0 |
| Cornea Week 84 | 0 | 0 |
| Cornea Week 100 | 0 | 0 |
| Cornea Week 104 | 0 | 0 |
| Cornea Week 116 | 0 | 0 |
| Cornea Week 132 | 0 | 0 |
| Cornea Week 148 | 0 | 0 |
| Cornea Week 160 | 0 | 0 |
| Anterior Chamber 68 | 0 | 0 |
| Anterior Chamber 84 | 0 | 0 |
| Anterior Chamber 100 | 0 | 0 |
| Anterior Chamber 104 | 0 | 0 |
| Anterior Chamber 116 | 0 | 0 |
| Anterior Chamber 132 | 0 | 0 |
| Anterior Chamber 148 | 0 | 0 |
| Anterior Chamber 160 | 0 | 0 |
| Iris Week 68 | 0 | 0 |
| Iris Week 84 | 0 | 0 |
| Iris Week 100 | 0 | 0 |
| Iris Week 104 | 0 | 0 |
| Iris Week 116 | 0 | 0 |
| Iris Week 132 | 0 | 0 |
| Iris Week 148 | 0 | 0 |
| Iris Week 160 | 0 | 0 |
| Lens Week 68 | 0 | 0 |
| Lens Week 84 | 0 | 0 |
| Lens Week 100 | 0 | 0 |
| Lens Week 104 | 0 | 0 |
| Lens Week 116 | 1 | 0 |
| Lens Week 132 | 0 | 0 |
| Lens Week 148 | 0 | 0 |
| Lens Week 160 | 0 | 0 |
| Vitreous Week 68 | 0 | 0 |
| Vitreous Week 84 | 0 | 0 |
| Vitreous Week 100 | 0 | 0 |
| Vitreous Week 104 | 0 | 0 |
| Vitreous Week 116 | 0 | 0 |
| Vitreous Week 132 | 0 | 0 |
| Vitreous Week 148 | 0 | 0 |
| Vitreous Week 160 | 0 | 0 |
| Retina Week 68 | 0 | 0 |
| Retina Week 84 | 0 | 0 |
| Retina Week 100 | 0 | 0 |
| Retina Week 104 | 0 | 0 |
| Retina Week 116 | 0 | 0 |
| Retina Week 132 | 0 | 0 |
| Retina Week 148 | 0 | 0 |
| Retina Week 160 | 0 | 0 |
| Optic nerve Week 68 | 0 | 0 |
| Optic nerve Week 84 | 0 | 0 |
| Optic nerve Week 100 | 0 | 0 |
| Optic nerve Week 104 | 0 | 0 |
| Optic nerve Week 116 | 0 | 0 |
| Optic nerve Week 132 | 0 | 0 |
| Optic nerve Week 148 | 0 | 0 |
| Optic nerve Week 160 | 0 | 0 |
| Macula Week 68 | 0 | 0 |
| Macula Week 84 | 0 | 0 |
| Macula Week 100 | 0 | 0 |
| Macula Week 104 | 0 | 0 |
| Macula Week 116 | 0 | 0 |
| Macula Week 132 | 0 | 0 |
| Macula Week 148 | 0 | 0 |
| Macula Week 160 | 0 | 0 |
| Choroid Week 68 | 0 | 0 |
| Choroid Week 84 | 0 | 0 |
| Choroid Week 100 | 0 | 0 |
| Choroid Week 104 | 0 | 0 |
| Choroid Week 116 | 0 | 0 |
| Choroid Week 132 | 0 | 0 |
| Choroid Week 148 | 0 | 0 |
| Choroid Week 160 | 0 | 0 |
| Periphery Week 68 | 0 | 0 |
| Periphery Week 84 | 0 | 0 |
| Periphery Week 100 | 0 | 0 |
| Periphery Week 104 | 0 | 0 |
| Periphery Week 116 | 0 | 0 |
| Periphery Week 132 | 0 | 0 |
| Periphery Week 148 | 0 | 0 |
| Periphery 160 | 0 | 0 |
Incidence of Change from normal or Abnormal, clinically insignificant to normal clinically significant
| eyes | Double Masked Group Vehicle Eyes | Double Masked Group Elamipretide Eyes |
|---|---|---|
| Conjunctiva Week 4 Normal to Abnormal Clinically significant | 1 | 0 |
| Conjunctiva: Week 8 Normal to Abnormal Clinically significant | 1 | 0 |
| Conjunctiva: Week 16 Normal to Abnormal Clinically significant | 1 | 1 |
| Conjunctiva: Week 28 Normal to Abnormal Clinically significant | 1 | 1 |
| Conjunctiva: Week 44 Normal to Abnormal Clinically significant | 1 | 1 |
| Lids: Week 28 Normal to Abnormal Clinically significant | 0 | 1 |
| Cornea: Week 32 Normal to Abnormal Clinically significant | 0 | 2 |
| Cornea: Week 44 Normal to Abnormal Clinically significant | 1 | 1 |
Double Masked: Dilated Fundus Changes from Baseline: Vehicle Eye and Elamipretide Eyes Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant
| eyes | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Double Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes | 0 | 0 |
Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant
| eyes | Vehicle Eyes | Elamipretide Eyes |
|---|---|---|
| Open Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes | 0 | 0 |
Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.
| score on a scale | Single Eye | Bilateral Eye |
|---|---|---|
| Week 52 | -3.8 ± 10.09 | -0.6 ± 19.72 |
| Week 56 (Follow-up Visit) | -5.8 ± 6.29 | — |
Collected over Up to 112 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| One Eye DM Period | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Both Eyes DM Period | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| (One Eye DM Period) OLE | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| (Both Eyes DM) OLE Period | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | One Eye DM Period | Both Eyes DM Period | (One Eye DM Period) OLE | (Both Eyes DM) OLE Period |
|---|---|---|---|---|
| Blood glucose decreasedInvestigations | 0/8 | 1/4 | 3/8 | 0/4 |
| HypersensitivityImmune system disorders | 1/8 | 1/4 | 0/8 | 0/4 |
| NasopharyngitisInfections and infestations | 2/8 | 1/4 | 2/8 | 1/4 |
| SinusitisInfections and infestations | 2/8 | 0/4 | 0/8 | 1/4 |
| InfluenzaInfections and infestations | 1/8 | 0/4 | 2/8 | 1/4 |
| Muscle strainInjury, poisoning and procedural complications | 0/8 | 1/4 | 0/8 | 0/4 |
| DysgeusiaNervous system disorders | 2/8 | 1/4 | 0/8 | 0/4 |
| NephrolithiasisRenal and urinary disorders | 0/8 | 1/4 | 0/8 | 0/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/8 | 0/4 | 0/8 | 0/4 |
| PyrexiaGeneral disorders | 0/8 | 0/4 | 0/8 | 1/4 |
All participants for whom age (continuous) was measured.
| Age, Continuous(years) | Group 2 | Group 3 | Total |
|---|---|---|---|
| Mean | 35.4 ± 14.47 | 30.0 ± 4.83 | 33.6 ± 12.11 |
| Sex: Female, Male(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 7 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 6 | 2 | 8 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 0 | 7 |
| More than one race | 0 | 4 | 4 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Elamipretide eye(Participants) | Group 2 | Group 3 | Total |
|---|---|---|---|
| right eye only | 4 | 0 | 4 |
| left eye only | 4 | 0 | 4 |
| both eyes | 0 | 4 | 4 |
| BMI(kg/m^2) | Group 2 | Group 3 | Total |
|---|---|---|---|
| Mean | 25.70 ± 3.937 | 29.43 ± 2.081 | 26.94 ± 3.796 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2016, a primary completion of Sep 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2021, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Optic Atrophy, Hereditary, Leber →
Stealth BioTherapeutics Inc. →